Kauser Sharieff
Low Vision Rehabilitation · Yorba Linda, CANPI 1033227665
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. 2024 is the largest year on record at $681, more than ten times the $20 reported in 2021.
Across 8 payments — averaging $91.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$150
- Sight Sciences, Inc.$125
- Coopervision Inc.$123
- Bausch & Lomb Americas Inc.$107
- LKC Technologies, Inc.$90
- Alcon$87
- plus $48 from 2 others
What the payments were for
- Food & beverage$729100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 1 | $150 |
| Sight Sciences, Inc. | 1 | $125 |
| Coopervision Inc. | 1 | $123 |
| Bausch & Lomb Americas Inc. | 1 | $107 |
| LKC Technologies, Inc. | 1 | $90 |
| Alcon | 1 | $87 |
| Johnson & Johnson Vision Care, Inc. | 1 | $28 |
| Glaukos Corporation | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$150
- TEARCARE SYSTEM$125
- MyDay Contact Lens$123
- INFUSE SVS$107
How this compares
$729 in reported general payments places this provider in the 60th percentile of 37 low vision rehabilitation providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 15 | $165 |
Paid to pharmacies, not to this prescriber.
Other low vision rehabilitation in Yorba Linda
- Lyly UngSan Francisco$9K
- Joseph LayaRedding$2K
- Shirley HongRowland Heights$2K
- Andrew PhillipsArcadia$1K
- Linda YeeSan Jose$1K
- Grace JengOakland$1K
- Tiffany ChanSan Francisco$1K
- Andy ChenLong Beach$1K
- David ShinFontana$1K
- Leangsok TeaWestminster$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.